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1. Introduction 
Combined liver and kidney transplant (CLKT) is the procedure of choice for patients with 
both liver and kidney end-stage-disease. In addition, patients with polycystic liver or kidney 
disease or with hyperoxaluria, or those with cirrhosis and acute renal failure, including 
hepatorenal syndrome receiving hemodialysis (HD) for more than two months, may also 
benefit of CLKT. 
The decision to transplant both, the liver and kidney, is more difficult in cases when kidney 
dysfunction may be temporary. Hepatorenal syndrome is a potentially reversible renal 
failure caused by advance liver disease. Currently, the treatment of choice of hepatorenal 
syndrome is liver transplant alone and not a combined liver/kidney transplant.  
The model for end-stage liver disease (MELD) replaced the United Network for Organ 
Sharing status classification for the allocation of liver organs. Due to the heavily weighted 
serum creatinine value in the calculation of the MELD score, candidates with renal failure 
have received organs more rapidly. As a result there has been considerable increase in 
number of combined liver-kidney transplants in the past few years. 
The reason to propose both liver and kidney transplant for patients with cirrhosis and renal 
failure relays on the negative impact that renal failure has on patients submitted to liver 
transplant alone (LTA). Results of several studies show that renal failure in patients with 
chronic liver disease is associated with high mortality and morbidity after liver transplant 
alone. Nevertheless, it’s very hard to identify a cut-off point of renal dysfunction that 
determines those patients who may benefit from combined liver and kidney transplant 
instead of liver transplant alone. 
In this chapter, we will review the main points to be considered when evaluating candidates 
for combined liver kidney transplant, as well as some concerns that have not been yet 
clarified. 
2.Assessment of renal function and evaluating of CLKT in patients with end 
stage liver disease 
Renal failure in cirrhotic patients is associated with poor prognosis. It is well known that 
cirrhotic patients with renal failure have decreased survival when compared to patients 
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with normal renal function. This negative effect is also evident when these patients undergo 
liver transplantation, as shown by reduced graft and patient survival. 
Ideally, patients with a high probability of developing end stage renal disease after liver 
transplantation alone should receive a combination of liver and kidney transplant. 
However, is still a great challenge to identify these patients who are at higher risk. 
The presence and the severity of pretransplant kidney failure are factors independently 
associated with postoperative sepsis, need for renal replacement therapy and poor graft and 
patient outcomes.  
In addition to the degree of renal dysfunction, duration and cause of renal failure should 
also be considered when evaluating candidates for liver transplantation alone or combined 
liver kidney transplantation.  
Patients with pretransplant renal dysfunction (defined as pretransplant Scr > 1.5mg/dL) for 
a period longer than 12 weeks showed higher probability of progression to end-stage renal 
disease at 3 years post transplant. However in this study the etiology of renal dysfunction 
was not specified, mainly due to the authors concern of potential bias in classifying renal 
failure in absence of kidney biopsy.  
Renal failure is usually defined by a reduction in glomerular filtration rate (GFR) that can be 
acute when it occurs in hours to weeks or chronic when it occurs gradually over time.  
Currently, serum creatinine remains the most widely used method to assess renal function 
in cirrhotic patients.  
However, patients with liver dysfunction have reduced creatinine production secondary to 
loss of muscle mass, and therefore, in those patients serum creatinine usually overestimates 
renal function. As the Cockroft-Gauld and MDRD (Modification of Diet in Renal Disease) 
formulas are based on serum creatinine concentration, adjusted by race, age, sex and weight, 
they also overestimate renal function in patients with cirrhosis and should not be used in 
clinical settings.  
In this context, cystatin C has emerged as an option for evaluate renal function since its level 
is not influenced by muscle mass. Nevertheless, its value has not been well established and 
is not available as standart test.  
More accurate methods, such as determination of inulin clearance or radionuclide markers, 
represent the gold standard for measuring glomerular filtration rate. Indeed, its use in daily 
attendance is not feasible, because of its complexity, making repeated measurements that these 
patients often require difficult. These gold standard methods should be indicated for selected 
patients when there is a need to accurately assess renal function to decide between performing 
liver transplantation alone or CKLT. Their routinary use, however, is not mandatory. 
Beyond the degree of renal function, the etiology of renal failure should be assessed, as 
prognosis varies according to the cause of renal failure. In a recent study with a large 
population of hospitalized patients with cirrhosis, the most common cause of renal failure 
was due to bacterial infections (46%), followed by hypovolemia (32%), hepatorenal 
syndrome (13%) and intrinsic nephropathy (9%). Patients with HRS and bacterial infections 
had lower 3-month survival compare to patients with intrinsic nephropathy. Even though 
patients with intrinsic nephropathy present better survival among all causes of renal failure 
in cirrhosis, its chronic form of renal failure has a non-reversible character and are most 
likely to receive CKLT. 
The diagnostic diagram of etiology of renal failure include a complete medical history and 
physical examination, searching for presence of diabetes and/or hypertension as well as any 
other evidence of organ damage. Laboratory evaluation should include urinalysis to seek for 
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signs of intrinsic nephropathy, like hematuria, pyuria, cell and granular casts, and 24h urine 
collection to assess protein excretion. 
In addition to urine test, a renal ultrasonography, is useful in evaluating preexisting renal 
disease. Findings such as alteration of renal echogenicity and reductions in the size of the 
kidneys indicate the existence of chronic kidney disease.  
Finally, a definitive diagnostic may require the realization of a renal biopsy, which may also 
give prognostic information. In patients with intrinsic nephropathy, marked 
tubulointerstitial injury is associated with progression to end stage renal disease, even if the 
primary disease is a glomerulopathy. Among histological findings, the degree of tubular 
interstitial fibrosis is the most powerful predictor of subsequent progression of renal 
impairment. There are very limited data on renal biopsies findings in cirrhotic patients. A 
study evaluated 23 kidney biopsies performed in liver transplant candidates with renal 
failure of unknown etiology or persisted HRS (> 4 weeks) demonstrated a variety of 
pathologic findings. These included menbranoproliferative glomerulopathy, IgA 
nephropathy, diabetes nephropathy and acute tubular necrosis. Of note, 4 patients showed 
normal histology. In this study CLKT was recommended for 10 of 26 patients with > 40% 
global glomeruloesclerosis, > 30% of interstitial fibrosis or severe glomerular 
ischemia/injury. Although these histological criteria have not been evaluated in further 
studies in patients with cirrhosis, it suggests that renal histopathology changes may alter 
therapeutic management, including the need for combined liver and kidney transplant.  
Therefore according to a recent consensus, a renal biopsy should be performed in patients 
with an estimated glomerular filtration rate less than 30ml/min with a chronic course .The 
decision to perform a transjugular or percutaneous renal biopsy should take into account 
professional experience and patient’s clinical conditions, mostly platelet count and 
coagulation parameters. 
 Hepatorenal syndrome is a form of kidney failure that is secondary to a severe circulatory 
disorder in patients with cirrhosis. This particular complication of liver disease can be 
potentially reversible with the combination of systemic vasoconstrictors and intravenous 
albumin. Even though the definite treatment of this severe condition remains liver 
transplantation, the importance of pre-liver transplantation treatment should not be 
underestimate. Patients with HRS treated with systemic vasoconstrictors and albumin 
before liver transplantation and pretransplant serum creatinine inferior to 1.5 mg/dL had a 
three year survival similar to patients transplanted with normal renal function.  
Finally, the current criteria to perform CLKT according to the consensus conference is 
shown in table 1. 
 
1. Evidence of chronic kidney disease and renal biopsy demonstrating more than 30% of 
glomeruloesclerosis or 30% of interstitial fibrosis. 
2. If the biopsy is not possible, the decision is made based on National Kidney Foundation 
criteria for chronic kidney disease, which is an eGFR less than 30ml/min for more than 3 
months.  
3. Patients with end stage renal disease in renal replacement therapy 
4. Patients with hepatorenal syndrome or acute kidney injury with creatinine greater or 
equal to 2.0 mg/dL and on dialysis for more than 8 weeks. 
Table1. Indications for combined liver kidney transplant in patients with end stage liver 
disease. 
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3. Evaluation of candidates for CLKT in patients with end stage renal 
Disease (ESRD)  
The benefit of combined liver kidney transplantation is not well established for patients 
with compensated cirrhosis and ESRD. The decision to perform CLKT or only a liver 
transplant is matter of debate. In a study of patients with chronic hepatitis C on RRT who 
underwent kidney transplantation alone, the degree of liver fibrosis correlated with 
patient and graft survival at 3 years .It is recommended that patients with chronic liver 
disease and ESRD who are candidates for kidney transplantation should be sought for the 
presence of significant liver fibrosis and cirrhosis. These patients should be submitted to 
transjugular liver biopsy with assessment of hepatic venous pressure gradient(HVPG). 
Patients with cirrhosis and/or clinical significant portal hypertension, determined by an 
HVPG greater than 10mmHg should be referred to CLKT. The option of kidney 
transplantation alone should be offered for those patients without these characteristics. 
Even though most of the data regarding these situations comes from patients with 
cirrhosis due to hepatitis C, the recommendations are generally applied to all patients 
irrespective of etiology of cirrhosis. 
 
 
Combined Liver Kidney Transplantation
Portal Hypertension
> 10 mmHg
Kidney Transplant Alone
Normal
`
Wedge Hepatic Vein Pressure
Cirrhosis
Kidney Transplant Alone
No Cirrhosis
Liver Biopsy
Asymptomatic Liver Disease
Combined Liver and Kidney Transplantation
Symptomatic or Evidence of Portal Hypertension
End Stage Renal Disease
with
Liver Disease
 
 
 
Fig. 1. Diagram for End Stage Renal Disease and Liver Disease (adapted from Consensus 
Conference on Simultaneous Liver Kidney Transplantation). 
4. Outcomes in combined liver and kidney transplantation 
Cirrhosis may not be the only indication for CKLT. In a large series of 3520 patients 
evaluated between 1984-2008, the main indications for combined liver kidney 
transplantation were: hiperoxaluria type 1 (42.7%), liver cirrhosis and chronic renal failure 
(23.5%), polycystic liver and kidney disease (15.5%), liver cirrhosis with hepatorenal 
syndrome (7.1%) and end stage liver disease with renal failure of unknown cause (6%).  
Hence, prognosis and outcomes of combined liver kidney transplantation are not well 
known because most of the data came from series that include patients treated with CLKT 
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not only with end stage liver disease but also patients with inherited diseases without 
cirrhosis. 
In recent years, MELD score has increasingly been used for liver allocation. Due to the 
presence of serum creatinine in the formula of MELD score, candidates with renal failure are 
more likely to receive a liver graft. Although pre transplant renal failure is associated with 
poor outcomes in liver transplantation settings, this modification on organ allocation system 
was not followed by changes in survival. The 3-year survival of liver transplant recipients 
remained almost unchanged when compared pre and pos-MELD era (81% vs. 80%, 
respectively).  
A large case-control study compared the outcomes of patients submitted to liver transplant 
alone with or without renal failure to combined liver kidney transplants (CKLT) between 
1987 and 2006. After adjusting for multiple donor (age, race, cause of death) and recipient 
(MELD, dialysis status at time of transplant) characteristic’s, recipients of CLKT had a 
similar one-year survival compared to liver transplant alone (82 vs. 81.8%). However, the 
degree of renal failure in both groups was not described. The only subgroup in which CLKT 
had benefit on survival was in patients on long-term pre transplant hemodialysis (defined as 
a period equal to or greater than 12 weeks). In this subgroup, CKLT recipients had a higher 
survival than those submitted to liver transplantation alone (84.5% vs. 70.8%, P=0.008).  
Another study demonstrated that patients on hemodialysis prior to transplantation had  a 
significantly higher 1-year survival for CLKT group when compared to LT alone (79.4% vs. 
73.7%, p=0.004). This difference, however, was not observed when only patients with renal 
failure (defined by serum creatinine ≥ 2.5 mg/dL) not on dialysis where analyzed. In this 
subgroup, 1-year survival was similar for patients who received CLKT or liver transplant 
alone (81% vs.78.8%, p= n.s.). An important issue to highlight is that patients receiving 
CLKT, either on hemodialysis or not, had better liver function at the time of transplant 
compared to those receiving liver transplantation alone. Mean MELD score of patients 
receiving LTA or CKLT was 36 vs. 31 for recipients on hemodialysis, and 34 vs. 28 for those 
with renal failure (serum creatinine >2.5 mg/dl) but not on hemodialysis (p<0.01 for both 
comparisons).  
Most studies of survival in combined liver kidney transplantation analyzed a very 
heterogeneous population respect to the etiology of liver transplantation. Though, a recent 
study that only included patients with cirrhosis and chronic kidney disease, showed a 1-
year survival lower for patients treated with CKLT compared to liver transplant alone group 
(80 vs. 97%, p=0.014). The probability of survival at 3 years was also lower in the CLKT 
group, but the difference between both groups did not reach statistical significance (75% 
and 88%, respectively). The incidence of complications was also higher for CKLT. Patients 
with CLKT had a higher incidence of bacterial infections and transfusions requirements 
compared to LTA group. Nevertheless, the comparison group (liver transplant alone) did 
not present renal failure at the time of transplant (mean serum creatinine value of 0.96±0.27 
mg/dL), because all patients with cirrhosis and advanced chronic kidney disease (defined 
by a glomerular filtration rate below 30ml/min) were considered candidates for CLKT.  
Another important point is the potential reversibility of renal failure after liver 
transplantation. As mentioned previously, patients with HRS should be treated to reverse 
the renal failure before liver transplantation. Many of these patients, however, do not 
respond to treatment and eventually undergo CKLT.  Only a few single-center series had 
described outcomes of patients with hepatorenal syndrome submitted to CLKT. One of 
them compared the results of patients with HRS on hemodialysis who received CLKT (n=22, 
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median time of pretransplant hemodialysis of 41 days) to those with HRS on hemodialysis 
who received liver transplant alone (n=80, pretransplant hemodialysis time inferior to 30 
days). The one-year survival for patients undergoing CLKT or LTA was similar (72% vs. 
66%, respectively, p=0.88). Most of the benefit of performing CKLT was observed in patients 
on hemodialysis for more than 8 weeks pre transplant. This group had higher survival than 
those receiving CLKT on hemodialysis for a period inferior than 8 weeks (88% vs.66%, 
respectively). Among patients receiving liver transplantation alone, recovery of renal 
function was achieved in 90% of patients at one-month, even though most of them required 
hemodialysis at post transplant period.  
The possible benefit of CLKT on LTA in patients with hepatorenal syndrome was also 
evaluated in a study comparing patients submitted to CLKT to patients with HRS submitted 
to LTA.  Survival at 5 years was similar for CLKT recipients (48.1%) and patients with HRS 
receiving LTA (67.1%) (p=ns).  
Some recent data on patients who received CLKT (n=75) over a 23 year-period show 
excellent 1-, 3- and 5- year patients survival (81%, 73% and 67%, respectively). However, 
short-term mortality (< 90 days) was especially high because of sepsis/infection on 
postoperative period. In addition, there was no difference in patient survival based on 
whether or not a recipient was on dialysis pre-transplantion. Nevertheless, the need of post 
transplant renal replacement therapy was significantly associated with poor prognosis 
(p=0.0012). 
Regarding graft survival, it seems that the liver graft has an immune protective effect on 
kidney graft when both organs came from the same donor. A study comparing renal 
allograft outcomes of patients who undergone CLKT to kidney after liver transplantation 
(KALT) demonstrated a higher incidence of chronic rejection in KALT group than CLKT 
group (4.6 vs. 1.2%, P < 0.001). One and three-year rejection-free renal graft survival of 
KALT was lower than CLKT group (77% and 67% KALT vs. 85% and 78% CLKT, 
respectively; P < 0.001). Renal half-life of KALT allograft was shorter than CLKT group 
(6.6+/-0.9 vs. 11.7+/-1.3 years, P < 0.001). It has been speculated that this effect is secondary 
to the secretion of soluble HLA antigens by the liver and to phagocytosis of these reactive 
antibodies by kupffer cells. 
Although many theories have been described to explain the possible hepatic protection on 
renal graft, some recent findings have questioned this statement. A case report of acute 
humoral rejection in kidney allograft in an ABO compatible CLKT was described. Even 
treating, the humoral rejection with plasmapheresis, intravenous immunoglobulin and 
rituximab, the kidney required 3 months to recovery function and finally progressed to 
chronic allograft nephropathy. 
5. Combined liver and kidney transplantation in special conditions 
Polycystic kidney diseases (PKD) compass a group of inherited diseases that causes an 
irreversible decline in kidney function. Autosomal dominant polycystic kidney disease 
(ADPKD) is associated with cysts in the kidneys and, in many cases, cysts in the liver and 
pancreas. The autosomal dominant form (ADPKD) is the most common genetic cause of 
chronic kidney disease .As survival with dialysis or transplant increase, incidence of liver 
disease will also increase. When cysts are diffused, fenestration/resection procedures are 
not successful and LKA offers a good survival option. For combined liver and kidney 
transplantation one- and two-year patient survival rates were similar to combined 
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transplantation for other indications. For patients with acceptable renal function at time of 
transplantation, solitary liver transplantation has an excellent outcome.  
Primary hyperoxaluria (PHO) is a rare metabolic disorder with autosomal recessive 
inheritance.  PHO is induced by one of two enzymatic defects, both of which result in 
markedly enhanced conversion of glyoxalate to poorly soluble oxalate which is then 
excreted in the urine. Combined liver-kidney transplantation is probably the treatment of 
choice for children with type 1 PHO with progressive renal disease. The liver provides the 
missing enzyme, thereby lowering oxalate production to the normal range. The outcome 
may be best if transplantation is performed when the GFR falls to 25 mL/min per 1.73 m2 
and prior to marked tissue oxalate deposition. Isolated liver transplantation has been 
proposed for patients with rapidly progressive disease who still have a glomerular filtration 
rate above 30 mL/min per 1.73 m2. 
6. Conclusion 
Since implementation of MELD score as an organ allocation system, a crescent number of 
cirrhotic patients with renal failure has been submitted to CLKT. Due to increase shortage of 
organ donors, is of outstanding importance to define  which are the patients who benefit 
most of this procedure. 
The decision to perform orthotopic transplant alone or combined kidney-liver 
transplantation is still challenging, mainly because there is not enough data on factors that 
can predict renal function recovery. In patients with possible reversible causes of kidney 
dysfunction, including those with hepatorenal syndrome and acute renal failure, it is 
difficult to precise the boundaries between functional and irreversible damage. Therefore, in 
these cases kidney biopsy should be encouraged in order to evaluate interstitial and 
glomerular injury.  
Combined liver kidney transplantation seems to be an adequate treatment in patients with 
end stage liver disease and chronic kidney disease on renal replacement therapy, as well as 
for those with inherited disease. The survival advantage in others subsets of patients is not 
well established and more studies are needed.  
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